Amrutanjan Health Care
- Market cap
- ₹ 1,422 Cr.
- P/E
- 69.7x
- P/B
- 3.88x
- 52-week range
- 476.5 – 760.15
- ROE
- 19%
- ROCE
- 25%
- Dividend yield
- 1%
- Debt / equity
- 0
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Amrutanjan Health Care Limited is an India-based company, which is engaged in the business of manufacturing, supplying and sale of products in pain management, congestion management, beverages, and hygiene and services in pain management. Its segments include OTC Products, Women Hygiene, Beverages and Others. The OTC Products segment is engaged in manufacturing products for pain management, congestion management and hygiene. The Women Hygiene includes Comfy Snug Fit, Comfy Snug Fit Extra Long, and Comfy Snug Fit Ultra XL. The Beverages segment is engaged in manufacturing fruit juices and oral hydration drinks. The Others segment includes the pain management center. The Company’s pain management products include Pain Balm Extra Power, Strong Pain Balm, New Maha Strong Pain Balm, Roll on and Advanced Back Pain + Roll-On, among others. Its congestion management products include Relief Cold Rub, Relief Nasal Inhaler, Relief Cough Syrup and Relief Swas Mint.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Amrutanjan Health Care against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)69.7 against a typical 34.3: pricier than most peers (1st = cheapest).175th of 220
- Sales growth+9.5% against a typical +15.6% from a year earlier.116th of 197
- Profit growth−47.4% against a typical +18.9% from a year earlier.131st of 160
- Share price, 3 months−4.1% against a typical −0.5%.117th of 200
- Size₹ 1,421.8 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).79th of 199
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
Adequate safety
Rated A by CARE- No warnings from the agency.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| CARE | CARE A | Stable | 31 Jul 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 31 Jul 2026 | New rating | CARE A | — | CARE | — |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 3 Nov 2026Upcoming | Financial Results/Dividend | To consider and approve the financial results for the period ended September 30, 2026 and dividend |
| 11 Aug 2026 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2026 |
| 8 May 2026 | Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2026 and dividend |
| 3 Feb 2026 | Financial Results/Dividend | To consider and approve the financial results for the period ended December 31, 2025 and dividend |
| 10 Nov 2025 | Financial Results/Dividend | To consider and approve the financial results for the period ended September 30, 2025 and dividend |
| 12 Aug 2025 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2025 |
| 15 May 2025 | Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2025 and dividend |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 99 | 117 | 127 | 84 | 110 | 123 | 135 | 94 | 118 | 141 | 150 | 103 |
| Expenses | 92 | 95 | 111 | 80 | 96 | 99 | 118 | 86 | 101 | 116 | 124 | 97 |
| Operating Profit | 7 | 22 | 16 | 4 | 14 | 23 | 18 | 8 | 17 | 25 | 26 | 6 |
| OPM % | 6.9% | 18.4% | 12.8% | 4.2% | 12.4% | 19% | 13.1% | 9% | 14% | 17.9% | 17.1% | 6.1% |
| Other Income | 4 | 4 | 5 | 4 | 4 | 4 | 5 | 4 | 4 | 3 | −3 | 2 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Profit before tax | 9 | 24 | 20 | 6 | 16 | 26 | 21 | 11 | 19 | 26 | 21 | 6 |
| Tax % | 25.6% | 26.4% | 30.3% | 27.2% | 26% | 25.9% | 27.2% | 26.4% | 27.3% | 26.2% | 22.9% | 28.1% |
| Net Profit | 7 | 17 | 14 | 5 | 12 | 19 | 15 | 8 | 14 | 19 | 16 | 4 |
| EPS in Rs | 2.37 | 6.04 | 4.72 | 1.6 | 4.08 | 6.66 | 5.25 | 2.87 | 4.83 | 6.73 | 5.6 | 1.51 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 11%
- 5 Years
- 9%
- 3 Years
- 10%
- TTM
- 11%
- 10 Years
- 12%
- 5 Years
- 1%
- 3 Years
- 17%
- TTM
- 14%
- 10 Years
- 9%
- 5 Years
- −6%
- 3 Years
- −7%
- TTM
- —
- 10 Years
- 19%
- 5 Years
- 18%
- 3 Years
- 17%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Amrutanjan Health Care | ₹ 495.70 | ₹ 1,422 Cr. | 69.7x | 3.9x | 19% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Sambhu Prasad Sivalenka
- Executive Chairman of the Board, Managing Director
- N. Swaminathan
- Chief Financial Officer
- Mani Bhagavatheeswaran
- Chief Marketing Officer
- Gagan Preet Singh
- General Manager - Legal, Company Secretary & Compliance Officer
- S. Jeyakanth
- Chief Operating Officer - Supply Chain and Product Delivery
- Soumomoy Pal
- Associate Vice President - Information Technology
- J. Ravichandran
- Associate Vice President - QC/ QA/ R&D
Prices are delayed and for information only. Nothing on this page is investment advice.